{"preliminary_commentary":{"by_channel":{"x_thread":4},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"NCT05281406","nct_id":"NCT05281406","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct05281406. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"all patients received a platinum-based chemotherapy (carboplatin/pemetrexed or cisplatin/pemetrexed) for a maximum of 4 cycles (q3w) in combination with 80 mg Osimertinib daily","label":"Osimertinib in combination with platinum-based chemotherapy","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2026-11","type":"ESTIMATED"},"conditions":["NSCLC Stage IIIB","NSCLC Stage IV"],"enrollment":{"count":50,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Osimertinib","otherNames":["Tagrisso"],"type":"DRUG"},{"name":"Pemetrexed","otherNames":[],"type":"DRUG"},{"name":"Cisplatin","otherNames":[],"type":"DRUG"},{"name":"Carboplatin","otherNames":[],"type":"DRUG"}],"last_update":"2025-02-21","lead_sponsor":"Goethe University","official_title":"Additional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)","overall_status":"RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2025-11","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression Free Survival (PFS1)","timeFrame":"2 years"}],"references":[],"start_date":{"date":"2021-11-12","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Additional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)","url":"https://clinicaltrials.gov/study/NCT05281406"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct05281406"}